Vor Biopharma Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / NTS GMT
Robert Ang - Vor Biopharma Inc. - President & CEO

Hello. My name is Robert Ang. I am privileged to be CEO and President of Vor Bio. Vor is a biotechnology company focused on trying to cure blood cancers through cell and genome engineering. I will point you to our disclaimer slide, which you can read on our website at your leisure.

So what we're trying to do in Vor is we are trying to revolutionize blood cancers by changing the way patients are receiving transplants. And so in many different kinds of blood cancers, the standard of care was actually invented around 50 years ago.

With transplantation, you could take cells from the same patient or an allogeneic donor -- the stranger who is matched to the patient -- and actually transplant those cells permanently into the patient to replace the bone marrow. And so that was really a revolution in its time where it wasn't possible -- thought to be possible previously, and can provide really lasting clinical benefits for patients, even some cures.

Unfortunately, in the majority of people who are transplanted, the cancer returns. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot